CD117: The Essential Guide to CD117 (c‑KIT) in Health, Disease and Therapy

CD117, also known as the c‑KIT receptor, is a pivotal protein in human biology. This article offers a thorough, reader‑friendly overview of CD117, its normal roles, how it operates at the cellular level, and why it matters in disease—from common tumours to rarer haematological disorders. You’ll find clear explanations of the science behind CD117, practical notes for clinicians and insights into current and emerging therapies that target this important receptor.

What is CD117?

CD117 is the cluster of differentiation name for the receptor tyrosine kinase known as c‑KIT. It sits on the surface of various cell types and binds to its ligand, stem cell factor (SCF). When SCF engages CD117, the receptor dimerises and autophosphorylates, triggering a cascade of intracellular signals that regulate cell survival, proliferation and migration. In clinical language, CD117 functions as both a marker and a functioning receptor that can influence cell fate decisions.

In standard laboratory reporting, you may see the receptor written as CD117, c‑KIT or KIT. In some texts you will also encounter the alternative gene name KIT, which reflects the gene that encodes the receptor. For practical purposes in patient care and research, CD117 and c‑KIT refer to the same protein and its activity, with CD117 commonly used in pathology and diagnostic contexts.

How CD117 works: Signalling and function

The ligand: Stem cell factor (SCF)

SCF is the natural ligand for CD117. It exists in both soluble and membrane‑bound forms and plays a crucial role in stem cell biology. Binding of SCF to CD117 promotes receptor dimerisation and activation, allowing signals to propagate inside the cell. This initial step is essential for normal development, tissue repair and the maintenance of certain stem cell populations.

Downstream signalling pathways

Once activated, CD117 engages multiple signalling pathways that regulate cell fate. The principal routes include:

• PI3K/AKT pathway: supports cell survival and metabolic activity.
• RAS/MAPK pathway: promotes cell proliferation and differentiation.
• JAK/STAT pathway: contributes to gene expression changes that influence growth and survival.

These pathways do not operate in isolation; they cross‑talk with other signals in the cell’s environment. The precise outcome depends on the cell type, the context of other signals, and the presence or absence of SCF. In normal tissue, CD117 signalling helps regulate the formation of blood cells, pigment cells, and cells of the gut lining, among other functions.

CD117 in normal physiology

CD117 is expressed in a diverse set of tissues and cell lineages. Key physiological roles include:

• Haematopoiesis: CD117 marks haematopoietic stem and progenitor cells, supporting the maintenance of the blood cell repertoire throughout life.
• Pigmentation: melanocytes rely on CD117 signalling for development and survival, contributing to normal pigmentation.
• Gastrointestinal system: interstitial cells of Cajal, which coordinate gut motility, express CD117 and depend on SCF signalling for their function and survival.
• Reproductive tissues: certain reproductive tract cells show CD117 expression, reflecting roles in cellular turnover and repair.

In clinical practice, the presence or absence of CD117 expression can help distinguish among cell types and disease processes. For example, in pathology, CD117 staining is used to help identify certain tumours and to characterise their lineage, although the precise interpretation depends on the tissue and clinical context.

CD117 as a biomarker in disease

CD117 gains particular importance as a biomarker in several conditions. The best‑documented areas of relevance are gastrointestinal stromal tumours (GIST) and systemic mastocytosis, with additional implications in various haematological disorders.

Gastrointestinal stromal tumours (GIST)

GISTs are the most common mesenchymal tumours of the digestive tract. A hallmark feature in most GISTs is expression of CD117 on tumour cells, detectable by immunohistochemistry. However, while CD117 positivity supports the diagnosis, the story is more nuanced because a minority of GISTs are CD117 negative and rely on alternative markers such as DOG1 (ANO1) or other receptor tyrosine kinases for confirmation.

Beyond diagnosis, CD117 is central to rät therapy decisions. The vast majority of GISTs harbour activating mutations in the KIT gene (KIT encodes the CD117 receptor). These mutations drive constitutive receptor activity, independent of SCF binding. The specific mutation type can influence response to targeted therapies and overall prognosis. In clinical terms, testing for KIT mutations complements CD117 IHC to tailor treatment plans.

Systemic mastocytosis and KIT mutations

Systemic mastocytosis is characterised by abnormal mast cell accumulation in tissues and often involves activating mutations in KIT. CD117 positivity on mast cells is a standard finding in tissue biopsies. KIT mutations here commonly occur in the juxtamembrane region (notably KIT D816V in many adult patients), leading to ligand‑independent receptor activity. Therapeutic implications include consideration of targeted inhibitors, though mutation type can influence drug sensitivity.

Acute myeloid leukaemia and other haematological malignancies

In acute myeloid leukaemia (AML) and certain other haematological malignancies, CD117 expression is frequently observed on blasts. In these diseases, the presence of CD117 alone does not establish a diagnosis, but it contributes to characterising the disease and can influence risk stratification and therapeutic choices. KIT mutations can co‑exist in AML, and when present, they may offer opportunities for kinase‑inhibitor therapies in selected subtypes, though clinical benefit varies among patients.

KIT mutations: Implications for disease and therapy

The KIT gene encodes the CD117 receptor, and mutations alter receptor function. In GIST, the most clinically relevant mutations occur in specific exons, causing constitutive activation that drives tumour growth. The pattern of mutations across exons 9, 11, 13 and 17 has practical consequences for prognosis and treatment response.

Common mutation patterns and their consequences

• Exon 11 mutations: The most common in GIST; often associated with a strong response to imatinib, especially in tumours with gastric origin, though responses can vary with specific mutation subtype.
• Exon 9 mutations: Frequently found in tumours of intestinal origin; may respond less robustly to standard doses of imatinib and sometimes require higher dosing or alternative agents.
• Exons 13 and 17 mutations: Less common but still clinically relevant; these can influence sensitivity to certain TKIs and may necessitate tailored approaches.

In systemic mastocytosis and other KIT‑driven conditions, mutation type and allele burden can affect disease behaviour and therapeutic options. The landscape of KIT mutations is complex, and comprehensive molecular profiling helps clinicians optimise treatment decisions.

Testing for KIT mutations

Diagnosis and management increasingly rely on an integrated approach that combines immunohistochemistry for CD117 with molecular testing for KIT mutations. Techniques include targeted sequencing of KIT exons with next‑generation sequencing panels, enabling precise mutation identification. In GIST, mutation testing informs prognosis and guides the choice and dosing of tyrosine kinase inhibitors (TKIs). In mastocytosis and other KIT‑driven diseases, mutation data can influence eligibility for clinical trials and targeted therapies.

Diagnostic and therapeutic implications of CD117 in clinical practice

CD117 testing is a routine tool in pathology and haematology, guiding both diagnosis and treatment. The practical implications span several domains:

Immunohistochemistry (IHC) for CD117

IHC staining for CD117 helps pathologists identify KIT‑expressing tumours. In GIST, the presence of CD117 supports the diagnosis, but pathologists consider the full histological and molecular context. In other tissues, CD117 staining can help differentiate cell lineages and narrow the differential diagnosis for spindle cell tumours, melanocytic lesions and certain haematological malignancies.

Molecular testing and personalised therapy

Beyond staining, sequencing KIT to identify activating mutations is increasingly standard practice in GIST. The mutation profile can predict response to first‑line imatinib and inform the choice of second‑line or third‑line TKIs such as sunitinib and regorafenib, or newer agents for specific mutation subsets. In systemic mastocytosis, molecular testing for KIT mutations augments diagnostic certainty and helps guide targeted therapies under specialist guidance.

Targeted therapies: Imatinib and beyond

Imatinib was the first targeted agent to demonstrate significant activity against KIT‑mutant tumours. It binds to the inactive form of the CD117 receptor, preventing autophosphorylation and downstream signalling. In GIST, imatinib remains a cornerstone of therapy, particularly for unresectable or metastatic disease. If resistance develops, alternative TKIs such as sunitinib or regorafenib may be employed, with decisions tailored to mutation status, tumour origin and patient tolerance. In PDGFRA‑mutant GISTs, or in specific mutation contexts, targeted agents like avapritinib have shown activity and represent a modern expansion of options for KIT‑related cancers.

CD117 testing in clinical practice: Practical considerations

For clinicians and laboratories, a practical understanding of CD117 testing helps ensure accurate diagnosis and effective patient care. Considerations include tissue handling, assay selection and interpretation in the light of evolving evidence.

Accurate CD117 assessment often relies on high‑quality tissue samples from biopsy or surgical specimens. IHC for CD117 is widely available, but interpretation should occur in the context of histology, the patient’s clinical picture and complementary tests such as DOG1 staining or KIT mutation analysis. In certain tumours, CD117 positivity can be seen in non‑GIST lesions, so pathologists use a panel of markers to avoid diagnostic pitfalls.

Interpretation centres on the combination of CD117 staining pattern, intensity and the presence of KIT mutations. In GIST, strong CD117 positivity with a known KIT activating mutation supports the diagnosis and informs therapy. In other tumours or haematological diseases, CD117 positivity must be integrated with additional data to avoid misclassification and to direct appropriate management.

In GIST, mutation type and tumour site influence prognosis and risk of progression. With systemic therapies, ongoing assessment of response to TKIs, side effects and tolerability is essential. Regular imaging and mutation‑driven adjustments to therapy are common in modern practice, aiming to balance disease control with quality of life.

Emerging research and future directions for CD117

The field around CD117 continues to evolve. Researchers are exploring the nuances of receptor signalling, resistance mechanisms to TKIs and the potential for combination therapies that target multiple pathways involved in KIT‑driven tumours. Innovative diagnostic methods, including liquid biopsy approaches for monitoring KIT mutations and real‑time assessment of treatment response, hold promise for more precise and timely decision‑making. In haematology, understanding how CD117 marks stem cell populations can influence regenerative medicine and transplant strategies in the longer term.

Practical considerations for patients and carers

Understanding CD117 and KIT mutations can help patients make informed decisions about treatment options. If you or a loved one has a KIT‑driven cancer or a haematological condition with CD117 expression, discussing mutation status, expected responses to TKIs, and potential side effects with a specialist is important. Hydroxyurea, cytotoxic agents and emerging targeted therapies may be part of a comprehensive treatment plan, depending on the exact diagnosis and mutation profile. Patients should report symptoms such as swelling, fatigue, skin changes or unusual rashes promptly, as these can reflect ongoing treatment effects or disease activity.

CD117 in research: a note on terminology and consistency

In scientific writing, you may encounter a mix of CD117, c‑KIT and KIT references. While all point to the same receptor, using CD117 in clinical and pathology discussions helps standardise terminology for readers and patients alike. Where relevant, it is helpful to mention both CD117 and c‑KIT to bridge laboratory conventions and broader scientific literature. The occasional occurrence of lowercase ‘cd117’ in informal notes should not appear in formal medical writing; aim for the conventional uppercase form in professional settings, while maintaining consistency within a document.

Conclusion: CD117 as a unifying thread in biology and medicine

CD117 sits at a crossroads of normal physiology and disease. From guiding the survival and activity of haematopoietic stem cells to driving the growth of KIT‑mutant tumours, the receptor’s activity has real‑world implications for diagnosis, prognostication and therapy. The combination of CD117 immunohistochemistry with detailed KIT mutation profiling equips clinicians to tailor treatment strategies, minimise unnecessary interventions and improve patient outcomes. As research advances, new therapeutic options and refined diagnostic tools will continue to clarify the role of CD117 in health and disease, ensuring that patients receive timely, personalised care grounded in the most current science.